UPDATE: Canaccord Genuity Downgrades Momenta Pharmaceuticals (MNTA) to Hold; Negative Copaxone Ruling

June 25, 2012 7:37 AM EDT Send to a Friend
Get Alerts MNTA Hot Sheet
Price: $15.07 +1.76%

Rating Summary:
    8 Buy, 2 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 19 | New: 37
Trade MNTA Now!
Join SI Premium – FREE
(Updated - June 25, 2012 8:23 AM EDT)

Canaccord Genuity downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Buy to Hold with a price target of $12.00 (from $17.00).

Analyst, Ritu Baral, said, "M-enox revenues are now a modest royalty stream. Friday’s negative ruling on Copaxone delays potential launch of M356 (generic Copaxone). While MNTA's Baxter-partnered biosimilars program and branded drugs have significant long-term potential, lack of near-term catalysts likely limits 12-month upside."

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $17.01 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities

Canaccord Genuity

Add Your Comment